130 related articles for article (PubMed ID: 16256998)
1. Conservative therapy of stage I endometrial adenocarcinoma and atypical endometrial hyperplasia for the preservation of fertility.
Chang WH; Chen CH; Yu MH
Int J Gynaecol Obstet; 2006 Feb; 92(2):137-8. PubMed ID: 16256998
[No Abstract] [Full Text] [Related]
2. [Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey].
Le Digabel JF; Gariel C; Catala L; Dhainaut C; Madelenat P; Descamps P
Gynecol Obstet Fertil; 2006 Jan; 34(1):27-33. PubMed ID: 16406735
[TBL] [Abstract][Full Text] [Related]
3. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
4. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.
Kaku T; Yoshikawa H; Tsuda H; Sakamoto A; Fukunaga M; Kuwabara Y; Hataeg M; Kodama S; Kuzuya K; Sato S; Nishimura T; Hiura M; Nakano H; Iwasaka T; Miyazaki K; Kamura T
Cancer Lett; 2001 Jun; 167(1):39-48. PubMed ID: 11323097
[TBL] [Abstract][Full Text] [Related]
5. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia.
Wang Y; Zhou R; Wang H; Liu H; Wang J
Int J Gynecol Cancer; 2019 May; 29(4):699-704. PubMed ID: 30826750
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma.
Guillon S; Popescu N; Phelippeau J; Koskas M
Int J Gynaecol Obstet; 2019 Sep; 146(3):277-288. PubMed ID: 31197826
[TBL] [Abstract][Full Text] [Related]
7. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
8. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Yamagami W; Susumu N; Makabe T; Sakai K; Nomura H; Kataoka F; Hirasawa A; Banno K; Aoki D
J Gynecol Oncol; 2018 Mar; 29(2):e21. PubMed ID: 29400014
[TBL] [Abstract][Full Text] [Related]
9. Analysis of adjuvant endocrine therapy on the prognosis of endometrial carcinoma confined to the uterus.
Wang Z; Wang J; Wei L
Int J Gynaecol Obstet; 2007 Aug; 98(2):162-3. PubMed ID: 17585918
[No Abstract] [Full Text] [Related]
10. [Extended endometrial ablation risks in the fertility sparing management of adenocarcinoma and atypical hyperplasia of the endometrium].
Gonthier C; Luton D; Koskas M
Gynecol Obstet Fertil; 2015 Mar; 43(3):185-6. PubMed ID: 25708847
[No Abstract] [Full Text] [Related]
11. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
12. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia.
Lowe MP; Cooper BC; Sood AK; Davis WA; Syrop CH; Sorosky JI
Gynecol Oncol; 2003 Dec; 91(3):569-72. PubMed ID: 14675678
[TBL] [Abstract][Full Text] [Related]
13. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.
Ricciardi E; Maniglio P; Frega A; Marci R; Caserta D; Moscarini M
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1934-7. PubMed ID: 23242719
[TBL] [Abstract][Full Text] [Related]
14. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
[TBL] [Abstract][Full Text] [Related]
15. The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia.
Ichinose M; Fujimoto A; Osuga Y; Minaguchi T; Kawana K; Yano T; Kozuma S
Int J Gynecol Cancer; 2013 Feb; 23(2):288-93. PubMed ID: 23314282
[TBL] [Abstract][Full Text] [Related]
16. Two successful pregnancies after in vitro fertilization and embryo transfer in a patient with endometrial atypical hyperplasia bordering on adenocarcinoma treated conservatively with high-dose progesterone.
Piura B
Gynecol Obstet Invest; 2006; 61(1):21-3. PubMed ID: 16131806
[TBL] [Abstract][Full Text] [Related]
17. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40.
Randall TC; Kurman RJ
Obstet Gynecol; 1997 Sep; 90(3):434-40. PubMed ID: 9277658
[TBL] [Abstract][Full Text] [Related]
18. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery.
Koskas M; Bendifallah S; Luton D; Daraï E; Rouzier R
Fertil Steril; 2012 Nov; 98(5):1229-35. PubMed ID: 22959452
[TBL] [Abstract][Full Text] [Related]
19. Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer.
Hurst SA; Hartzfeld KM; Del Priore G
Fertil Steril; 2008 Mar; 89(3):724.e1-3. PubMed ID: 17570366
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity alterations associated with progesterone therapy in endometrial hyperplasia and adenocarcinoma.
Yasuda M; Kotajima S; Kajiwara H; Takekoshi S; Osamura RY; Yoshitake T; Muramatsu T; Miyamoto T; Murakami M; Shinozuka T
Int J Gynecol Cancer; 2005; 15(1):155-62. PubMed ID: 15670311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
